196 related articles for article (PubMed ID: 34139461)
1. Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations.
Skromne-Eisenberg E; Treviño-Frenk I; Llamosa García Velázquez GL; Quiñones-Aguilar S; Rivas-Alonso V; Maza-Flores M; Macías-Islas MÁ; Llamas-López L; González-Amezquita V; León-Jiménez C; Medina-López Z; Ortiz-Maldonado JF; Santos-Diaz MA; Bertado-Cortés B; Flores-Rivera JJ; Ordóñez-Boschetti L
Mult Scler Relat Disord; 2021 Aug; 53():103053. PubMed ID: 34139461
[TBL] [Abstract][Full Text] [Related]
2. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
3. Survey of diagnostic and treatment practices for multiple sclerosis in Europe.
Fernández O; Delvecchio M; Edan G; Fredrikson S; Gionvannoni G; Hartung HP; Havrdova E; Kappos L; Pozzilli C; Soerensen PS; Tackenberg B; Vermersch P; Comi G
Eur J Neurol; 2017 Mar; 24(3):516-522. PubMed ID: 28139062
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study.
Tornatore C; Phillips JT; Khan O; Miller AE; Barnes CJ
Neurol Clin Pract; 2012 Mar; 2(1):48-57. PubMed ID: 23634358
[TBL] [Abstract][Full Text] [Related]
5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
6. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
8. Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional study.
Finkener S; Achtnichts L; Cervenakova M; Nedeltchev K; Findling O
Mult Scler Relat Disord; 2022 Dec; 68():104396. PubMed ID: 36544325
[TBL] [Abstract][Full Text] [Related]
9. Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data.
Boykо A; Fernández O; Alifirova V; Babicheva N; Bakhtiyarova K; Volkov A; Glavinskaya N; Goncharova Z; Greshnova I; Smagina I; Lashch N; Inzhinova A; Karnaukh V; Lukashevich I; Malkova N; Poverennova I; Sivertseva S; Sinitsina L; Khoroshilova N; Sherman M; Shchur S; Yampolskaya-Gosteva I; Melnikov M; Lozovskaya I
Mult Scler Relat Disord; 2021 Oct; 55():103201. PubMed ID: 34391041
[TBL] [Abstract][Full Text] [Related]
10. Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G; Arun T; Capela C; Laureys G; Jones E; Dominguez-Castro P; Sanchez-de la Rosa R; Hiltl S; Iaffaldano P
Mult Scler Relat Disord; 2023 Aug; 76():104770. PubMed ID: 37307690
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
12. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
13. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
Braune S; Rossnagel F; Dikow H; Bergmann A;
BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
[TBL] [Abstract][Full Text] [Related]
14. Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM.
Gisela Z; Carla P; Josefina B; Tomas I; Lucia B; Pappolla A; Miguez J; Patrucco L; Cristiano E; Norma D; Verónica T; Carlos V; Leila C; Alonso R; Garcea O; Silva B; Celica Y; Marrodan M; Gaitán MI; Correale J; Marcos B; Luciana L; Anibal C; Emanuel S; Eduardo K; Judith S; Dario T; Javier H; Pedro N; Felisa L; Pablo LA; Susana L; Patricio B; Raul P; Adriana C; Alejandra M; María Eugenia B; Contentti Edgar C; Amelia AP; Carolina M; Mariano C; Luciano R; Matias K; Eduardo K; María Celeste C; Maria Laura M; Santiago T; Mariela C; Fatima PC; Andres B; Geraldine L; Alonso Serena M; Juan Ignacio R; Marcos S;
Neurol Res; 2023 Feb; 45(2):112-117. PubMed ID: 36184106
[TBL] [Abstract][Full Text] [Related]
15. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
16. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
17. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
18. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
19. Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland.
Brola W; Adamczyk-Sowa M; Kułakowska A; Głażewska J; Smaga A; Bartosik-Psujek H
Neurol Neurochir Pol; 2022; 56(3):256-260. PubMed ID: 35766058
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
